HPLC-QTOF/MS-based metabolomics to explore the molecular mechanisms of Yiqi Fumai Lyophilized Injection in heart failure mice.
Guang-Ying YuanZe-Liang LiuQiong LaiFei FuLu ZhangJun-Ping KouBo-Yang YuFang LiPublished in: Journal of separation science (2021)
Chronic heart failure is a common and fatal disease triggered by loss of normal cardiac function. Yiqi Fumai Lyophilized Injection is widely used in the treatment of cardiovascular diseases, especially chronic heart failure. In this study, a model of chronic heart failure in mice was established with permanent coronary artery ligation followed by Yiqi Fumai Lyophilized Injection intervention for 14 days. Then, the endogenous metabolites of mice plasma and urine samples were screened through nontargeted metabolomics techniques. The results indicated that Yiqi Fumai Lyophilized Injection treatment changed the metabolic pattern of chronic heart failure and regulated valine, leucine, and isoleucine biosynthesis, taurine and hypotaurine metabolism, histidine metabolism and arginine biosynthesis, etc. Finally, the cardioprotective mechanism of Yiqi Fumai Lyophilized Injection was further verified in the mouse model of chronic heart failure and angiotensin II-induced cardiac fibroblasts based on metabolomics. The results showed that Yiqi Fumai Lyophilized Injection could inhibit myocardial fibrosis to improve chronic heart failure. This study firstly elucidated the metabolic network and pathways regulated by Yiqi Fumai Lyophilized Injection, which might facilitate the realization of the clinically accurate application of Yiqi Fumai Lyophilized Injection in the treatment of chronic heart failure.
Keyphrases
- ejection fraction
- ultrasound guided
- mass spectrometry
- heart failure
- ms ms
- angiotensin ii
- coronary artery
- mouse model
- left ventricular
- cardiovascular disease
- type diabetes
- multiple sclerosis
- randomized controlled trial
- nitric oxide
- transcription factor
- adipose tissue
- oxidative stress
- liquid chromatography
- pulmonary artery
- cardiac resynchronization therapy
- pulmonary hypertension
- liver fibrosis
- cell wall
- replacement therapy